Latest Conference Articles

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma.

The survival benefit obtained from consolidation treatment with durvalumab after concurrent chemoradiation may change the standard of care for limited-stage small cell lung cancer.

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer.

Patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation.

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with myelofibrosis.

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Frontline amivantamab plus lazertinib outperformed osimertinib regarding progression-free survival in patients with high-risk EGFR-mutant non-small cell lung cancer.

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with advanced classical Hodgkin lymphoma.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Lorlatinib, compared with crizotinib, prolonged PFS and improved time to intracranial progression in ALK-positive non–small cell lung cancer.

Community urology practices have routinely used darolutamide in both doublet and triplet regimens to treat metastatic hormone-sensitive prostate cancer.

Nadofaragene firadenovec resulted in durable antitumor activity at 5 years in patients with BCG-unresponsive NMIBC either with carcinoma in situ or papillary disease.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Most survivors of stage I-III breast cancer who attempted pregnancy succeeded, though there were certain factors that seemed to increase the chance of conception.

Using an artificial intelligence-based navigation tool to contact patients who missed their colonoscopy appointment may help them reschedule and potentially attend a new appointment.

Adding capivasertib to fulvestrant was shown to improve the time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Compared with chemotherapy alone, atezolizumab plus chemotherapy did not improve overall survival in select patients with early relapsing triple-negative breast cancer.

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

After reviewing the evidence, nurses switched from heparin-based flushes to all saline flushes for patients disconnecting chemotherapy at home.

An oncology nurse explains how her institution created a surgical path card that improved wait times and patient satisfaction in adults undergoing cancer surgery.

The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.

The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost savings from less drug waste.

The newly appointed president of the Oncology Nursing Society (ONS) discussed healthcare policies that she and ONS will continue to advocate for in the cancer space.

Poor sleep quality among those with lung cancer and COPD emphasize the need to develop effective assessment strategies.